Melanoma costs: A dynamic model comparing estimated overall costs of various clinical stages

Dermatology Online Journal

Volumn 15, Issue 11, 2009, Pages

  Alexandrescu, Doru Traian ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; TEMOZOLOMIDE;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CLINICAL EXAMINATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COST; HEALTH CARE COST; HUMAN; MELANOMA; SENTINEL LYMPH NODE BIOPSY; TERMINAL CARE; COMPARATIVE STUDY; EARLY DIAGNOSIS; ECONOMICS; FEMALE; MALE; PATHOLOGY; SKIN TUMOR; STATISTICAL MODEL; TUMOR RECURRENCE; UNITED STATES;

CALIFORNIA; COST OF ILLNESS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MELANOMA; MODELS, ECONOMIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 71649102620     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. http://seer.cancer.gov/, accessed October 2008.
2. Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol. 2008;128:2905-2908 [PubMed]
3. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD [UI:]
4. American Cancer Society. Cancer Reference Information. Skin Cancer-Melanoma 2009. www.cancer.org, accessed November 2009.
5. Porzsolt F, Kirner A, Kaplan RM. Predictors of successful cancer prevention programs. Recent Results Cancer Res. 2009;181:19-31 [PubMed]
6. Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol. 1998;38:669-680 [PubMed] (Pubitemid 28213708)
7. Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J. Lifetime and Treatment-Phase Costs Associated With Colorectal Cancer: Evidence from SEER-Medicare Data. Clin Gastroenterol Hepatol. 2009;7:198-204 [PubMed]
8. González-Larriba JL, Serrano S, Alvarez-Mon M, et al. Costeffectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur J Cancer. 2000;36:2344-2352 [PubMed] (Pubitemid 30947830)
9. www.nccn.com, accessed January 2009.
10. Romero JB, Stefanato CM, Kopf AW, Bart RS. Follow-up recommendations for patients with stage I malignant melanoma. J Dermatol Surg Oncol. 1994;20:175-178 [PubMed]
11. Govindan R. Melanoma, in DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology Review. Lippincott Williams & Wilkins 2005 ISBN 0-7817-5278-5287
12. Linette GP. Emerging Therapies for Melanoma. The American School of Oncology. www. asoncology.com, accessed July 2008.
13. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648 [PubMed]
14. Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003;10:569-574 [PubMed]
15. Balch CM. Surgical management of regional lymph nodes in cutaneous melanoma. J Am Acad Dermatol. 1980;3:511-524 [PubMed]
16. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989;124:1051-1055 [PubMed] (Pubitemid 19231243)
17. Fincher TR, McCarty TM, Fisher TL, et al. Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. Am J Surg. 2003;186:675-681 [PubMed]
18. Zalaudek I, Horn M, Richtig E, Hodl S, Kerl H, Smolle J. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol. 2003;148:703-708 [PubMed] (Pubitemid 36629748)
19. Pidhorecky I, Lee RJ, Proulx G, et al. Risk factors for nodal recurrence after lymphadenectomy for melanoma. Ann Surg Oncol. 2001;8:109-115 [PubMed] (Pubitemid 32199406)
20. Urist MM, Balch CM, Soong S, Shaw HM, Milton GW, Maddox WA. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer. 1985;55:1398-1402 [PubMed] (Pubitemid 15143422)
21. Schmid-Wendtner MH, Baumert J, Eberle J, Plewig G, Volkenandt M, Sander CA. Disease progression in patients with thin cutaneous melanomas (tumour thickness < or = 0.75 mm): clinical and epidemiological data from the Tumour Center Munich 1977-98. Br J Dermatol. 2003;149:788-793 [PubMed] (Pubitemid 37412000)
22. Lens MB, Dawes M, Newton-Bishop JA, Goodacre T. Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg. 2002;89:1223-1227 [PubMed] (Pubitemid 36002537)
23. Wagner JD, Ranieri J, Evdokimow DZ, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg. 2003;112:486-497 [PubMed] (Pubitemid 36951438)
24. Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer. 2006;107:2436-2445 [PubMed]
25. Kang JC, Wanek LA, Essner R, Faries MB, Foshag LJ, Morton DL. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol. 2005;23:4764-4770 [PubMed] (Pubitemid 46224080)
26. Shen P, Wanek LA, Morton DL. Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? Ann Surg Oncol. 2000;7:554-559 [PubMed]
27. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89:1019-1025 [PubMed]
28. Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol. 1995;13:2104-2108 [PubMed]
29. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol. 1997;4:252-258 [PubMed] (Pubitemid 127725252)
30. Johnson TM, Fader DJ, Chang AE, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol. 1997;4:396-402 [PubMed]
31. Bassères N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology. 1995;191:199-203 [PubMed]
32. Hengge UR, Wallerand A, Stutzki A, Kockel N. Costeffectiveness of reduced follow-up in malignant melanoma. J Dtsch Dermatol Ges. 2007;5:898-907 [PubMed]
33. Butler L, Downe-Wamboldt B, Melanson P, et al. Prevalence, correlates, and costs of patients with poor adjustment to mixed cancers. Cancer Nurs. 2006;29:9-16 [PubMed] (Pubitemid 44309587)
34. Crott R. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review. Pharmacoeconomics. 2004;22:569-580 [PubMed] (Pubitemid 38943102)
35. Catlin A, Cowan C, Hartman M, Heffler S; National Health Expenditure Accounts Team. National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood). 2008 Jan-Feb;27(1):14-29. [PubMed]
36. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. Natl Cancer Inst. 2008;100:888-897 [PubMed] (Pubitemid 351881955)
37. Yabroff KR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007;99:14-23 [PubMed]
38. Hernández Martín A, Núñez Reiz A, Sáiz Martínez M, Rovirosa i Juncosa J. Cost per episode of care in the surgical treatment of skin cancer. Gac Sanit. 2006;20:273-279 [PubMed]
39. Hillner BE, Agarwala S, Middleton MR.Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. J Clin Oncol. 2000;18:1474-1480 [PubMed] (Pubitemid 30205393)
40. Cormier JN, Xing Y, Ding M, Cantor SB, Salter KJ, Lee JE, Mansfield PF, Crott R. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review. Pharmacoeconomics. 2004;22:569-580 [PubMed] (Pubitemid 38943102)
41. Lidgren M, Wilking N, Jonsson B, Rehnberg C. Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care. 2007;23:223-231 [PubMed] (Pubitemid 46642729)
42. Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care. 2007;45:154-159 [PubMed]
43. Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007;109:518-527. Erratum in: Cancer. 2007;109:2155 [PubMed]